11/03/2016 - 10:59am

Benzer Pharmacy will be delivering Novartis’s limited-distribution drug Cosentyx through five of its locations. 

11/01/2016 - 12:32pm

Pfizer has discontinued the global clinical development program around its investigational high cholesterol treatment bococizumab, which will impact their guidance. 

11/01/2016 - 11:28am

The $1.7 billion acquisition brings two potential treatments for non-alcoholic steatohepatitis (NASH) to Allergan’s global research and development pipeline. 

10/28/2016 - 1:31pm
Bloomberg BNA is reporting that the Food and Drug Administration’s director of the Center for Drug Evaluation and Research’s Office of New Drugs told an audience at the DIA Biosimilars Conference that manufacturers looking to submit an application for biosimilar approval should know what the FDA is looking for when evaluating a biosmilar for approval. Jenkins said that rather than the focus on safety and efficacy it places on standalone biologics, with biosimilars, it focvuses on how closely it resembles the reference product, something he called “a work in progress” for some drug makers. (Bloomberg BNA)
10/28/2016 - 10:54am

In a move that would expand its oncology pipeline, Astellas Pharma announced Friday its agreement to acquire Ganymed Pharmaceuticals for €422 million, or about $461 million. 

10/27/2016 - 10:56am
Crain’s Detroit Business is reporting that Flint, Mich.-based Diplomat Pharmacy’s stock is feeling the effect of Tuesday announcement that president Gary Kadlec and the company’s CFO Sean Whelan would be departing the company by year’s end. After the announcement, the company’s shares fell 12.36% Wednesday, the report says, hitting a new 52-week low. The company is set to release its Q3 earnings report next week. (Crain’s Detroit Business)
10/26/2016 - 12:13pm
10/26/2016 - 11:28am

Diplomat Pharmacy has announced big changes to its leadership team, including a new president and the departure of its CFO.

10/26/2016 - 11:05am

Among the reasons for the  name change was the organization’s expansion beyond its founders’ focus on biotechnology.